In vitro immune modulation by antibodies coupled to tumour cells.
Modification of autologous tumour cells to express the immune costimulator B7.1 is a potential strategy for immunotherapy of cancer. Previously, this has involved introduction of genetic material into cells, in vitro culture, and confirmation of the protein product on the cell surface. This is possi...
Main Authors: | Darling, D, Galea-Lauri, J, Gäken, J, Towner, P, Kuiper, M, Hollingsworth, S, Hirst, W, Barnard, A, Buggins, A, Mufti, G, Farzaneh, F |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1997
|
Similar Items
-
Induction of tumour rejection by B7.1 and IL-2 expressing tumour cells
by: Gaken, J, et al.
Published: (1997) -
Induction of tumour rejection by autologous and allogeneic tumour cells expressing B7.1 and IL-2.
by: Hirst, W, et al.
Published: (1996) -
An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.
by: Chan, L, et al.
Published: (2006) -
Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.
by: Gaken, J, et al.
Published: (1997) -
Tumour cells expressing B7.1 costimulatory molecule: Are these better targets for NK cells?
by: GaleaLauri, J, et al.
Published: (1996)